MarketPeel
Insider Trading Intelligence
DS

David A. Santos

RIGL
EVP, CHIEF COMMERCIAL OFFICER · RIGEL PHARMACEUTICALS INC · CIK 0001820066
FILING MIX · LIFETIME71%/29%
BUYS
20
SELLS
8
TOTAL VALUE
$464.0K
COMPANIES
1
ACTIVE SINCE
Aug 2020
HOLDINGS NOW
7,394
AVG SELL PX
$13.66
TRADE KIND
SHOWING 28 / 28
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 2 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by David A. Santos, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+60.00%-1.29%+0.24%-1.54%-0.68%
14d5+80.00%-4.08%+0.58%-4.66%-3.42%
30d5+60.00%+7.17%-1.08%+8.25%-0.73%
60d5+60.00%-8.81%-4.44%-4.37%-1.57%
90d5+60.00%-11.66%-1.47%-10.19%-2.31%
180d5+80.00%-8.24%+8.27%-16.51%-19.32%
1y5+20.00%+49.12%+18.86%+30.26%+53.18%
2y5(2 pending)+0.00%+145.64%+44.30%+101.34%+157.19%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
RIGL · 7,394 shares · as of Jun 17, 2026
090,903181,806272,709363,612202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 20 buys / 8 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
7,3947,394Jun 17, 2026Jun 22, 2026View →
RIGL
RIGEL PHARMACEUTICALS INC
SALE
EVP, Chief Commercial Officer
874$29.86$26.1K61,996Jun 1, 2026Jun 3, 2026View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
19,43062,870Feb 17, 2026Feb 19, 2026View →
RIGL
RIGEL PHARMACEUTICALS INC
SALE
EVP, Chief Commercial Officer
3,546$34.62$122.8K43,440Feb 10, 2026Feb 12, 2026View →
RIGL
RIGEL PHARMACEUTICALS INC
SALE
EVP, Chief Commercial Officer
5,718$36.01$205.9K46,986Feb 2, 2026Feb 4, 2026View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
7,3947,394Sep 15, 2025Sep 17, 2025View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
7,8507,850Mar 17, 2025Mar 19, 2025View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
6,8756,875Mar 17, 2025Mar 19, 2025View →
RIGL
RIGEL PHARMACEUTICALS INC
SALE
EVP, Chief Commercial Officer
1,796$21.93$39.4K51,704Feb 5, 2025Feb 6, 2025View →
RIGL
RIGEL PHARMACEUTICALS INC
SALE
EVP, Chief Commercial Officer
2,125$20.92$44.5K53,500Feb 4, 2025Feb 6, 2025View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
19,71755,625Jan 29, 2025Jan 31, 2025View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
14,78814,788Jan 29, 2025Jan 31, 2025View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
8,0008,000Nov 25, 2024Nov 26, 2024View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
78,50078,500Feb 28, 2024Mar 1, 2024View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
80,00080,000Feb 28, 2024Mar 1, 2024View →
RIGL
RIGEL PHARMACEUTICALS INC
SALE
EVP, Chief Commercial Officer
8,918$1.14$10.2K349,093Feb 5, 2024Feb 6, 2024View →
RIGL
RIGEL PHARMACEUTICALS INC
SALE
EVP, Chief Commercial Officer
5,601$1.13$6.3K358,011Feb 2, 2024Feb 6, 2024View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
157,000157,000Jan 23, 2024Jan 25, 2024View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
209,000363,612Jan 23, 2024Jan 25, 2024View →
RIGL
RIGEL PHARMACEUTICALS INC
SALE
EVP, Chief Commercial Officer
5,388$1.66$8.9K144,612Feb 2, 2023Feb 6, 2023View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
160,000160,000Jan 26, 2023Jan 30, 2023View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
50,000100,000Jan 26, 2023Jan 30, 2023View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
80,000150,000Jan 26, 2023Jan 30, 2023View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
50,00050,000Dec 28, 2022Dec 30, 2022View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
50,00060,000Jan 24, 2022Jan 26, 2022View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
100,000100,000Jan 24, 2022Jan 26, 2022View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
137,500137,500Jan 27, 2021Jan 28, 2021View →
RIGL
RIGEL PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
250,000250,000Aug 19, 2020Aug 20, 2020View →
Other insiders · RIGL
Loading peer insiders…
About this filer
CIK 0001820066
ROLE
EVP, Chief Commercial Officer
PRIMARY
RIGL
COMPANIES
1
ACTIVE SINCE
Aug 2020
MARKETPEEL · /INSIDER/0001820066DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback